This HFSA Heart Failure seminar will examine the cardiovascular impact of cancer therapies, with a focus on the recognition and management of treatment-related cardiotoxicity. Presentations will include a case-based discussion of immune checkpoint inhibitor–associated myocarditis, an overview of anthracycline and HER2-related cardiotoxicity, and practical treatment strategies.
This activity is intended for trainees, fellows, physicians, APPs, nurses, pharmacists and pharmacologists who care for patients with heart failure.
At the conclusion of this activity, learners will be better able to:
- Recognize the clinical presentation, diagnostic evaluation, and management strategies for ICI-associated myocarditis.
- Evaluate strategies for mitigating risk in patients with cancer therapy-related cardiac dysfunction.
Program Agenda
All sessions are listed in Eastern Standard Time.
Welcome Remarks
Elizabeth Ashley Hardin, MD, FHFSA
Immune Checkpoint Inhibitor - Associated Myocarditis: A Case-Based Discussion of Diagnosis and Management
Jean Kim, MD
TBD
Diego Sadler, MD
What Is an Ounce of Prevention Worth? Prevention and Management Strategies for Cancer Therapy-Related Cardiac Dysfunction
Andrew Bagnola, PharmD
Panel Discussion
End of Seminar